Eli Lilly (LLY)

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.

Eli Lilly signed a licensing deal with Juvena for muscle health using its AI-enabled stem-cell protein screening platform.

If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.

The fast-food giant was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.

The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.

The company is planning to soon begin combination studies, testing two of its drugs in weight loss.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.

China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.